BioPharm International-01-01-2021

After a hectic 2020, biopharma looks to deliver on COVID-19 vaccines and move other promising therapies forward.

Essential bio/pharma employees show hard work and dedication can pay off, for patients.

Advances in development, data management, and automation, and closer collaboration with contract development and manufacturing partners, are pushing more therapies closer to commercialization.

Cell-culture optimization may see benefits from a synthetic biology-based approach that improves product titer, quality, and time.

The development of an innovative purification process simplifies downstream processing for biologics.

Creativity and collaboration are required to overcome complex method development challenges.

Packaging and transporting large quantities of COVID-19 vaccines pose challenges for the cold chain.

Clear understanding of what exactly the biomolecule entails is essential.

Outsourcing increases as the industry balances development and manufacturing of both COVID-19 treatments and non-pandemic-related medicines.

The incoming administration faces key decisions on drug testing and access as well as vaccine distribution challenges.

Shutting down the COVID-19 pandemic requires a global, selfless effort.

Updating the quality technical agreement will clarify any expectations and limitations, says Siegfried Schmitt, vice president, Technical at Parexel.